Analysis | Published:

Trends in GPCR drug discovery: new agents, targets and indications

Nature Reviews Drug Discovery volume 16, pages 829842 (2017) | Download Citation

Abstract

G protein-coupled receptors (GPCRs) are the most intensively studied drug targets, mostly due to their substantial involvement in human pathophysiology and their pharmacological tractability. Here, we report an up-to-date analysis of all GPCR drugs and agents in clinical trials, which reveals current trends across molecule types, drug targets and therapeutic indications, including showing that 475 drugs (~34% of all drugs approved by the US Food and Drug Administration (FDA)) act at 108 unique GPCRs. Approximately 321 agents are currently in clinical trials, of which ~20% target 66 potentially novel GPCR targets without an approved drug, and the number of biological drugs, allosteric modulators and biased agonists has increased. The major disease indications for GPCR modulators show a shift towards diabetes, obesity and Alzheimer disease, although several central nervous system disorders are also highly represented. The 224 (56%) non-olfactory GPCRs that have not yet been explored in clinical trials have broad untapped therapeutic potential, particularly in genetic and immune system disorders. Finally, we provide an interactive online resource to analyse and infer trends in GPCR drug discovery.

Key points

  • We report an analysis of all drugs and agents currently in clinical trials that act via G protein-coupled receptors (GPCRs) – the most intensively studied drug target family.

  • There are currently 475 drugs (~34% of all drugs approved by the FDA) that act on 108 unique GPCR targets.

  • Approximately 321 agents are currently in clinical trials, of which ~20% target 66 potentially novel GPCR targets that do not currently have an approved drug.

  • Biological drugs, allosteric modulators and biased agonists are becoming more frequent in clinical trials.

  • The major disease indications for GPCR modulators show a shift towards diabetes, obesity and Alzheimer disease, although other central nervous system disorders are also highly represented.

  • The 224 (56%) non-olfactory GPCRs that are yet to be explored in clinical trials have broad untapped therapeutic potential, particularly in genetic and immune system disorders.

  • Further trends in GPCR drug discovery can be analysed in an interactive resource in the GPCRdb database.

Access optionsAccess options

Rent or Buy article

Get time limited or full article access on ReadCube.

from$8.99

All prices are NET prices.

References

  1. 1.

    , & The druggable genome: evaluation of drug targets in clinical trials suggests major shifts in molecular class and indication. Annu. Rev. Pharmacol. Toxicol. 54, 9–26 (2014).

  2. 2.

    The IDG Knowledge Management Center. Unexplored opportunities in the druggable human genome. Nat. Rev. Drug Disc. (2016). Peer-reviewed poster outlining a major NIH programme to characterize the 'dark space' of major drug target families.

  3. 3.

    GPCRDb: a G-protein-coupled receptor database. Recept. Channels 2, 1–7 (1994).

  4. 4.

    & The GRAFS classification system of G-protein coupled receptors in comparative perspective. Gen. Comp. Endocrinol. 142, 94–101 (2005).

  5. 5.

    et al. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: Towards curated quantitative interactions between 1300 protein targets and 6000 ligands. Nucleic Acids Res. 44, D1054–D1068 (2016).

  6. 6.

    et al. International Union of Basic and Clinical Pharmacology. XC. Multisite pharmacology: recommendations for the nomenclature of receptor allosterism and allosteric ligands. Pharmacol. Rev. 66, 918–947 (2014).

  7. 7.

    , & Teaching old receptors new tricks: biasing seven-transmembrane receptors. Nat. Rev. Drug Discov. 9, 373–386 (2010).

  8. 8.

    , , & Biased ligands at G-protein-coupled receptors: promise and progress. Trends Pharmacol. Sci. 35, 308–316 (2014). A review discussing how biased ligands may deliver safer, better tolerated and more efficacious drugs, which highlights several biased ligands that are in clinical development.

  9. 9.

    et al. Glucagon-like peptide-1 and its class B G protein-coupled receptors: a long march to therapeutic successes. Pharmacol. Rev. 68, 954–1013 (2016).

  10. 10.

    , & Chemokine receptors as therapeutic targets: why aren't there more drugs? Eur. J. Pharmacol. 746, 363–367 (2015).

  11. 11.

    , , , & Metabotropic glutamate receptors as drug targets: what's new? Curr. Opin. Pharmacol. 20, 89–94 (2015).

  12. 12.

    & G protein-coupled receptors as therapeutic targets for multiple sclerosis. Cell Res. 22, 1108–1128 (2012).

  13. 13.

    et al. G protein-coupled receptors in cancer. Int. J. Mol. Sci. 17, 1320 (2016).

  14. 14.

    & G protein-coupled receptors: novel targets for drug discovery in cancer. Nat. Rev. Drug Discov. 10, 47–60 (2011).

  15. 15.

    , & Nanobodies and their use in GPCR drug discovery. Curr. Top. Med. Chem. 15, 2543–2557 (2015).

  16. 16.

    & Tools for GPCR drug discovery. Acta Pharmacol. Sin. 33, 372–384 (2012).

  17. 17.

    New paradigms in GPCR drug discovery. Biochem. Pharmacol. 98, 541–555 (2015).

  18. 18.

    , , , & Allostery and biased agonism at class B G protein-coupled receptors. Chem. Rev. 117, 111–138 (2017).

  19. 19.

    , & Emerging paradigms in GPCR allostery: implications for drug discovery. Nat. Rev. Drug Discov. 12, 630–644 (2013). A key review article on the therapeutic potential of allosteric ligands.

  20. 20.

    et al. Recent updates on GPCR biased agonism. Pharmacol. Res. 112, 49–57 (2016).

  21. 21.

    et al. GPCRdb: an information system for G protein-coupled receptors. Nucleic Acids Res. 44, D356–D364 (2016). A specialized GPCR database and analysis tool spanning structures, mutants, crystallization construct design, and drugs and indications.

  22. 22.

    et al. DrugBank 4.0: shedding new light on drug metabolism. Nucleic Acids Res. 42, D1091–D1097 (2014).

  23. 23.

    , , , & Alignment-free d2* oligonucleotide frequency dissimilarity measure improves prediction of hosts from metagenomically-derived viral sequences. Nucleic Acids Res. 45, 39–53 (2017).

  24. 24.

    et al. Open Targets: a platform for therapeutic target identification and validation. Nucleic Acids Res. 45, D985–D994 (2016).

  25. 25.

    , & How many drug targets are there? Nat. Rev. Drug Discov. 5, 993–996 (2006).

  26. 26.

    , & Trends in the exploitation of novel drug targets. Nat. Rev. Drug Discov. 10, 579–590 (2011).

  27. 27.

    et al. A comprehensive map of molecular drug targets. Nat. Rev. Drug Disc. 16, 19–34 (2017).

  28. 28.

    et al. Effect of abaloparatide versus placebo on new vertebral fractures in postmenopausal women with osteoporosis. JAMA 316, 722–733 (2016).

  29. 29.

    , , , & Efficacy and safety of fasiglifam (TAK-875), a G protein-coupled receptor 40 agonist, in Japanese patients with type 2 diabetes inadequately controlled by diet and exercise: a randomized, double-blind, placebo-controlled, phase III trial. Diabetes Obes. Metab. 17, 675–681 (2015).

  30. 30.

    2016 FDA drug approvals. Nat. Rev. Drug Discov. 16, 73–76 (2017).

  31. 31.

    , , & Opportunities for therapeutic antibodies directed at G-protein-coupled receptors. Nat. Rev. Drug Discov. 16, 1–24 (2017). A review on therapeutic antibodies targeting GPCRs and the current pipeline of agents in clinical trials.

  32. 32.

    & G protein-coupled receptors as targets for anti-diabetic therapeutics. Nat. Rev. Drug Discov. 15, 161–172 (2016).

  33. 33.

    et al. Angiotensin II for the treatment of vasodilatory Shock. N. Engl. J. Med. 377, 419–430 (2017).

  34. 34.

    & GPR40 agonists for the treatment of type 2 diabetes: life after 'TAKing' a hit. Diabetes. Obes. Metab. 17, 622–629 (2015).

  35. 35.

    & Allosteric modulation and functional selectivity of G protein-coupled receptors. Drug Discov. Today Technol. 10, e237–e243 (2013).

  36. 36.

    et al. ASD v3.0: unraveling allosteric regulation with structural mechanisms and biological networks. Nucleic Acids Res. 44, D527–D535 (2016).

  37. 37.

    & Development of allosteric modulators of GPCRs for treatment of CNS disorders. Neurobiol. Dis. 61, 55–71 (2014).

  38. 38.

    , & Polypharmacology: challenges and opportunities in drug discovery. J. Med. Chem. 57, 7874–7887 (2014).

  39. 39.

    et al. Polypharmacology of dopamine receptor ligands. Prog. Neurobiol. 142, 68–103 (2016).

  40. 40.

    et al. Tissue-based map of the human proteome. Science 347, 1260419 (2015).

  41. 41.

    , & Anatomical profiling of G protein-coupled receptor expression. Cell 135, 561–571 (2008).

  42. 42.

    Novel therapeutic GPCRs for psychiatric disorders. Int. J. Mol. Sci. 16, 14109–14121 (2015).

  43. 43.

    et al. Fingolimod (FTY720): discovery and development of an oral drug to treat multiple sclerosis. Nat. Rev. Drug Discov. 9, 883–897 (2010).

  44. 44.

    & The latest innovations in the drug pipeline for multiple sclerosis. Am. Health Drug Benefits 8, 448–453 (2015).

  45. 45.

    , , & Evidence for the efficacy and effectiveness of THC-CBD oromucosal spray in symptom management of patients with spasticity due to multiple sclerosis. Ther. Adv. Neurol. Disord. 9, 9–30 (2016).

  46. 46.

    & The role of G protein-coupled receptors in the pathology of Alzheimer's disease. Nat. Rev. Neurosci. 12, 73–87 (2011).

  47. 47.

    , , , & A clinical study of lupron depot in the treatment of women with Alzheimer's disease: preservation of cognitive function in patients taking an acetylcholinesterase inhibitor and treated with high dose lupron over 48 weeks. J. Alzheimers Dis. 44, 549–560 (2015).

  48. 48.

    , , , & Serotonin 5-HT6 receptor antagonists in Alzheimer's disease: therapeutic rationale and current development status. CNS Drugs 31, 19–32 (2017).

  49. 49.

    , , & The therapeutic potential of G-protein coupled receptors in Huntington's disease. Pharmacol. Ther. 128, 305–323 (2010).

  50. 50.

    et al. Arbaclofen in children and adolescents with autism spectrum disorder: a randomized, controlled, phase 2 trial. Neuropsychopharmacology 42, 1390–1398 (2017).

  51. 51.

    , , & Use of antidiabetic drugs in the U. S., 2003–2012. Diabetes Care 37, 1367–1374 (2014).

  52. 52.

    International Diabetes Federation. IDF Diabetes Atlas Sixth Ed. IDF (2013).

  53. 53.

    , & Type 2 diabetes mellitus: a review of current trends. Oman Med. J. 27, 269–273 (2012).

  54. 54.

    et al. A phase 2, randomized, dose-finding study of the novel once-weekly human GLP-1 analog, semaglutide, compared with placebo and open-label liraglutide in patients with type 2 diabetes. Diabetes Care 39, 231–241 (2016).

  55. 55.

    , & Targeting orphan G protein-coupled receptors for the treatment of diabetes and its complications: C-peptide and GPR146. J. Intern. Med. 281, 25–40 (2017).

  56. 56.

    , & GPR119: 'double-dipping' for better glycemic control. Endocrinology 149, 2035–2037 (2008).

  57. 57.

    , , , & Protein-coupled receptor 119 (GPR119) agonists for the treatment of diabetes: recent progress and prevailing challenges. J. Med. Chem. 59, 3579–3592 (2016).

  58. 58.

    et al. Dopaminergic drugs in type 2 diabetes and glucose homeostasis. Pharmacol. Res. 109, 74–80 (2016).

  59. 59.

    & Protein-coupled receptor signaling in stem cells and cancer. Int. J. Mol. Sci. 17, 707 (2016).

  60. 60.

    , & Overexpression of G protein-coupled receptors in cancer cells: involvement in tumor progression. Int. J. Oncol. 27, 1329–1339 (2005).

  61. 61.

    et al. Targeting CB2-GPR55 receptor heteromers modulates cancer cell signaling. J. Biol. Chem. 289, 21960–21972 (2014).

  62. 62.

    Can you teach old drugs new tricks? Nature 534, 314–316 (2016). A news feature on the repurposing of old drugs to overcome skyrocketing costs in drug development.

  63. 63.

    in Handbook of Biologically Active Peptides (ed. Kastin, A.) 869–874 (Academic Press, 2013).

  64. 64.

    , , , & International Union of Basic and Clinical Pharmacology. XCV. Recent advances in the understanding of the pharmacology and biological roles of relaxin family peptide receptors 1–4, the receptors for relaxin family peptides. Pharmacol. Rev. 67, 389–440 (2015).

  65. 65.

    , , , & Formyl peptide receptors at the interface of inflammation, angiogenesis and tumor growth. Pharmacol. Res. 102, 184–191 (2015).

  66. 66.

    et al. Insights into bombesin receptors and ligands: highlighting recent advances. Peptides 72, 128–144 (2015).

  67. 67.

    , & Bombesin-like peptides studies on food intake and social behaviour with receptor knock-out mice. Ann. Med. 32, 519–529 (2000).

  68. 68.

    et al. Physiology, signaling, and pharmacology of galanin peptides and receptors: three decades of emerging diversity. Pharmacol. Rev. 67, 118–175 (2015).

  69. 69.

    , & Galanin receptors as a potential target for neurological disease. Expert Opin. Ther. Targets 19, 1665–1676 (2015).

  70. 70.

    & Inhibitors of HIV-1 protease: a major success of structure-assisted drug design. Annu. Rev. Biophys. Biomol. Struct. 27, 249–284 (1998).

  71. 71.

    , , & Glivec (STI571, imatinib), a rationally developed, targeted anticancer drug. Nat. Rev. Drug Discov. 1, 493–502 (2002).

  72. 72.

    Development of neuraminidase inhibitors as anti-influenza virus drugs. Drug Dev. Res. 46, 176–196 (1999).

  73. 73.

    , , & Molecular pharmacologist's guide to G protein-coupled receptor crystallography. Mol. Pharmacol. 88, 536–551 (2015).

  74. 74.

    , & From G protein-coupled receptor structure resolution to rational drug design. J. Biol. Chem. 290, 19489–19495 (2015).

  75. 75.

    , , & Structures of G protein-coupled receptors reveal new opportunities for drug discovery. Drug Discov. Today 20, 1355–1364 (2015).

  76. 76.

    & Editorial overview: new technologies: GPCR drug design and function — exploiting the current (of) structures. Curr. Opin. Pharmacol. 30, vii–x (2016). Special issue with leading academic and industrial groups describing developments in technologies for structure-based drug design.

  77. 77.

    et al. Structure-based discovery of opioid analgesics with reduced side effects. Nature 537, 185–190 (2016). Computational drug design study to develop a drug that mimics the pain-relieving activity of opioid compounds but that has fewer side effects.

  78. 78.

    & Pharmacology: inside-out receptor inhibition. Nature 540, 344–345 (2016).

  79. 79.

    , & Structurally enabled discovery of adenosine A2A receptor antagonists. Chem. Rev. 117, 21–37 (2017).

  80. 80.

    & G-Protein-coupled receptors and signaling networks: emerging paradigms. Trends Pharmacol. Sci. 22, 368–376 (2001).

  81. 81.

    , & G protein pathways. Science 296, 1636–1639 (2002).

  82. 82.

    , , , & Genome duplication events and functional reduction of ploidy levels in sturgeon (Acipenser, Huso and Scaphirhynchus). Genetics 158, 1203–1215 (2001).

  83. 83.

    et al. Distinct profiles of functional discrimination among G proteins determine the actions of G protein-coupled receptors. Sci. Signal. 8, ra123 (2015).

  84. 84.

    , Parreiras- & A pluridimensional view of biased agonism. Mol. Pharmacol. 90 587–595 (2016).

  85. 85.

    et al. The dynamic process of ß2-adrenergic receptor activation. Cell 152, 532–542 (2013).

  86. 86.

    et al. A randomized, phase 2 study investigating TRV130, a biased ligand of the μ-opioid receptor, for the intravenous treatment of acute pain. Pain 157, 264–272 (2016).

  87. 87.

    Enhanced morphine analgesia in mice lacking β-arrestin 2. Science 286, 2495–2498 (1999).

  88. 88.

    , , , & Biased agonism of the angiotensin II type I receptor. Int. Heart J. 56, 485–488 (2015).

  89. 89.

    , & Allosteric and biased G protein-coupled receptor signaling regulation: potentials for new therapeutics. Front. Endocrinol. 5, 68 (2014).

  90. 90.

    In vivo veritas, the next frontier for functionally selective GPCR ligands. Methods 92, 64–71 (2016).

  91. 91.

    , & Gut chemosensing mechanisms. J. Clin. Invest. 125, 908–917 (2015).

  92. 92.

    , , , , et al. Commensal bacteria make GPCR ligands that mimic human signalling molecules. Nature 549 48–53 (2017).

  93. 93.

    , , , & Dietary metabolites and the gut microbiota: an alternative approach to control inflammatory and autoimmune diseases. Clin. Transl Immunol. 5, e82 (2016).

  94. 94.

    et al. Recognition of bacterial signal peptides by mammalian formyl peptide receptors. J. Biol. Chem. 290, 7369–7387 (2015).

  95. 95.

    , & Extrasensory perception: odorant and taste receptors beyond the nose and mouth. Pharmacol. Ther. 142, 41–61 (2014). A review summarizing the evidence for expression and function of odorant and taste receptors in tissues beyond the nose and mouth and highlighting their broad potential in physiology and pathophysiology.

  96. 96.

    et al. International Union of Basic and Clinical Pharmacology. XCIV. Adhesion G Protein-Coupled Receptors. Pharmacol. Rev. 67, 338–367 (2015).

  97. 97.

    et al. How ligands illuminate GPCR molecular pharmacology. Cell 170, 414–427 (2017). A review highlighting the many understudied GPCRs and new methods for the identification of tool compounds to elucidate their pharmacology.

  98. 98.

    et al. Allosteric 'beta-blocker' isolated from a DNA-encoded small molecule library. Proc. Natl Acad. Sci. USA 114, 1708–1713 (2017).

  99. 99.

    , , , & Cornerstones of CRISPR-Cas in drug discovery and therapy. Nat. Rev. Drug Discov. 16, 89–100 (2017).

Download references

Acknowledgements

The authors thank A. Hersey, S. M. Soisson, V. Chelliah, L. Jahn, K. Harpsøe and M. Shehata for their valuable comments on this work. D.E.G. has received financial support from the European Research Council (DE-ORPHAN 639125) and the Lundbeck Foundation (R163-2013-16327).

Author information

Affiliations

  1. Department of Drug Design and Pharmacology, Faculty of Health and Medical Sciences, University of Copenhagen, 2100 Copenhagen, Denmark.

    • Alexander S. Hauser
    •  & David E. Gloriam
  2. Department of Neuroscience, Functional Pharmacology, University of Uppsala, 751 05 Uppsala, Sweden.

    • Misty M. Attwood
    •  & Helgi B. Schiöth
  3. Department of Immunology, Genetics and Pathology, Science for Life Laboratory, University of Uppsala, 751 05 Uppsala, Sweden.

    • Mathias Rask-Andersen

Authors

  1. Search for Alexander S. Hauser in:

  2. Search for Misty M. Attwood in:

  3. Search for Mathias Rask-Andersen in:

  4. Search for Helgi B. Schiöth in:

  5. Search for David E. Gloriam in:

Competing interests

The authors declare no competing financial interests.

Corresponding author

Correspondence to David E. Gloriam.

Glossary

Allosteric sites

Sites for ligand binding to a receptor that are remote from the binding site of the physiological agonist (known as the orthosteric site).

Biased agonism

A newly discovered mechanism for potentially reducing drug side effects by using a surrogate agonist to preferentially activate a different intracellular signalling pathway from that of the physiological agonist.

Established GPCR targets

Herein defined as the targets of a drug approved by the US Food and Drug Administration.

Polypharmacology

Ligand binding to multiple targets, all of which contribute to the pharmacological response.

Modes of action

Receptor activity defined as ligand stimulation (agonism), blocking (antagonism), inhibition (inverse agonism), or negative or positive allosteric modulation.

About this article

Publication history

Published

DOI

https://doi.org/10.1038/nrd.2017.178